Greenwich Lifesciences Inc
NASDAQ:GLSI

Watchlist Manager
Greenwich Lifesciences Inc Logo
Greenwich Lifesciences Inc
NASDAQ:GLSI
Watchlist
Price: 25.5 USD 8.23% Market Closed
Market Cap: $353.2m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Greenwich Lifesciences Inc
NASDAQ:GLSI
325m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Greenwich Lifesciences Inc
Glance View

Market Cap
353.2m USD
Industry
Biotechnology

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.

GLSI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top